Pacific Software, Inc. Announces Completion of Change of Control with PurMinds Holdings Inc.; Confirms Occupancy of a GMP Production Facility; and OTCQX Uplisting Strategy
MWN-AI** Summary
Pacific Software, Inc., now operating as PurMinds Enterprises, Inc., has announced significant corporate developments following its completion of a change of control and reverse takeover (RTO) with PurMinds Holdings Inc., effective November 3, 2025. This strategic shift positions the company to leverage the burgeoning $1 trillion neurological health market under new management, introducing a clinical-stage mission aimed at early detection and intervention in neurological and psychiatric disorders through its innovative "4P Medicine" platform—Predictive, Preventive, Personalized, and Participatory.
The acquisition finalized on August 19, 2025, allows PurMinds to incorporate 10763942 CANADA INC., known for its advanced neuromedicine solutions. The company has received approval for a name change to PurMinds Enterprises, Inc., with applications for new ticker symbols submitted to FINRA.
On January 12, 2026, PurMinds confirmed full occupancy of a state-of-the-art 20,477 square foot GMP-compliant manufacturing and research facility, further bolstering its regulatory strategy. This facility, previously licensed for controlled substances and drug establishment, will expedite approvals from Health Canada and the U.S. FDA.
Moreover, PurMinds is executing a roadmap for uplisting to the OTCQX Best Market by securing a PCAOB-registered audit firm, with expectations for the transition in early 2026. The company's Annual Report on Form 10-K reflects its pre-merger financials, while the upcoming Quarterly Report for Q1 2026 will present consolidated financials following the RTO, marking a new era for PurMinds Enterprises, Inc. as it positions itself at the forefront of neuromedicine innovation.
MWN-AI** Analysis
Pacific Software, Inc. (OTC: PFSF), now transitioning to PurMinds Enterprises, Inc., is embarking on an ambitious journey into the neurological health market, significantly boosted by its completed change of control and recent acquisition of PurMinds Holdings Inc. This marks a pivotal shift for the company, aligning with a rapidly growing industry with unmet needs.
The immediate occupancy of a newly acquired GMP-compliant production facility strengthens the company’s operational foundation. By leveraging the facility's existing regulatory licenses, PurMinds is well-positioned to expedite product development and potentially navigate through Health Canada and U.S. FDA certifications effectively. Investors should keep a close eye on the company’s progress in attaining these certifications, as they would enhance its market credibility and allow for a faster route to commercialization.
Looking forward, the planned uplisting from the OTC Pink market to the OTCQX represents a key strategic move aimed at increasing investor confidence and attracting institutional investment. This transition, along with hiring specialized talent and clearing legacy liabilities, suggests a commitment to a robust corporate governance framework. The upcoming financial reports, particularly the 10-Q due on February 14, 2026, will serve as a critical indicator of PurMinds' operational health and financial strategy post-RTO.
Investors should consider the potential volatility associated with the completion of the RTO and the upcoming filings, which may initially result in fluctuations in stock price. However, the foundational changes being set in place, particularly the strong management vision and the strategic location of its operational facility, suggest that PFSF could become an attractive long-term investment in the burgeoning neurological health market.
In summary, while the immediate future may bring some uncertainties, PurMinds’ strategic restructuring and operational milestones position it favorably for potential growth and market expansion in a high-demand segment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
TALLAHASSEE, Fla., Jan. 19, 2026 /CNW/ - Pacific Software, Inc. (OTC: PFSF) (dba. PurMinds Enterprises, Inc. the "Company"), today announces the formal completion of its change of control and Reverse Takeover (RTO) transaction with PurMinds Holdings Inc. ("PurMinds"), effective November 3, 2025. This milestone marks the Company's strategic entry into the $1+ trillion neurological health market under a new management team and clinical-stage mission.
Completion of PurMinds Acquisition and Corporate Rebranding Following the Stock Purchase Agreement entered into on August 19, 2025, the Company has finalized the acquisition of PurMinds Holdings Inc., which owns all outstanding shares of 10763942 CANADA INC., a clinical-stage neuromedicine leader.
PurMinds leverages a "4P Medicine" platform—Predictive, Preventive, Personalized, and Participatory—for early detection and intervention of neurological and psychiatric conditions before irreversible damage occurs. In alignment with this new corporate identity:
- Name Change: A corporate name change to PurMinds Enterprises, Inc. has been officially approved and accepted by the State of Nevada.
- Name and Ticker Symbol Update: While currently trading as Pacific Software, Inc., final name and ticker symbol change applications have been submitted to FINRA for processing.
- Finalization of Post-RTO Capital Structure: In connection with the RTO completed on November 3, 2025, the Company is finalizing its post-closing capital structure. Pursuant to the terms of the Share Purchase Agreement, which established a 90/10 equity split, the Company is proceeding with the final issuance of Common shares to the PurMinds shareholders.
Furthermore, Management is concurrently addressing legacy Instructions to the Transfer Agent (ITAI) that predated the RTO transaction. Resolving these historical administrative items is a priority to ensure a clean and transparent share registry. These actions will be executed over the coming months to facilitate an orderly transition and maintain a stable market environment as the Company integrates its new management team and operations.
Jan 12, 2026 Occupancy: 20,477 Sq. Ft. Facility for Multi-Purpose R&D, Production and Licensing The Company is pleased to confirm it has taken full occupancy of a premier pharmaceutical manufacturing and R&D facility on Monday, January 12, 2026. This 20,477 sq. ft. turnkey site is engineered to strict cGMP standards and is a critical step in the Company's regulatory strategy.
While the Company is currently in the process of securing new licenses, this specific site previously held a Controlled Substance License and a Drug Establishment License (DEL). Management intends to leverage the facility's existing high-spec infrastructure—which includes ISO 8 clean room standards, seismic sensors, and advanced security—to expedite the attainment of essential Health Canada and U.S. FDA certifications.
Strategic Roadmap: OTCQX Uplisting and PCAOB Audit To increase transparency and broaden the investor base, the Company has initiated the process of engaging a PCAOB-registered audit firm. This is a critical prerequisite in the plan to uplist from the OTC Pink market to the OTCQX® Best Market, the highest tier of the OTC Markets. The Company projects this transition to occur in the first half of 2026.
Financial Reporting and Consolidation Update The Company has published its Annual Report on Form 10-K. Management wishes to clarify that because the RTO transaction was finalized on November 3, 2025, the 10-K for fiscal year-end of September 30, 2025 reflects the Company's financial status prior to the merger completion and does not represent the consolidated PurMinds entity.
The upcoming Quarterly Report on Form 10-Q, for the period ending December 31, 2025 (due February 14, 2026), will be the first consolidated filing to represent the full transaction, the recent capital raise, and the post-RTO share structure.
"Taking occupancy of the GMP facility on January 12 is an important physical piece of our transition," said Angelo Pizzuto, Treasury and COO of PurMinds. "This site is a 'license-ready' environment that allows us to upgrade our regulatory standing necessary to lead in the neuromedicine space. With the RTO complete, we are moving swiftly to clear legacy debt, hire specialized talent, and secure a PCAOB audit. The upcoming 10-Q will be the first true baseline of the strength and potential of PurMinds Enterprises, Inc."
About PurMinds Enterprises, Inc. PurMinds™ is a precision neuro-medicine development company pursuing breakthrough solutions to neurological and psychiatric disorders. Its clinical pipeline includes novel, neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. PurMinds champions a "4P Medicine" platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. PurMinds currently operates under a Health Canada issued Controlled Drugs and Substances License.
Forward-Looking Statements This press release contains forward-looking statements regarding the Company's future financial filings, ticker symbol changes, facility licensing, and the timing of the OTCQX uplisting. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.
SOURCE Pacific Software Inc.
FAQ**
How does the acquisition of PurMinds Holdings impact Pacific Software Inc PFSF's strategic positioning in the neurological health market, and what specific advantages does the "4P Medicine" platform provide in clinical development?
What are the implications of Pacific Software Inc PFSF's occupancy of the 20,477 sq. ft. GMP production facility for upcoming regulatory approvals from Health Canada and the U.S. FDA, and what is the timeline for these certifications?
Can you elaborate on the anticipated benefits of Pacific Software Inc PFSF's planned uplisting to the OTCQX Best Market, especially in terms of increased transparency and investor engagement following the PCAOB audit?
How will the upcoming Quarterly Report on Form 10-Q for Pacific Software Inc PFSF, reflecting the consolidated PurMinds entity, differ from the prior 10-K, and what key financial metrics should investors be monitoring post-RTO?
**MWN-AI FAQ is based on asking OpenAI questions about Pacific Software Inc (OTC: PFSF).
NASDAQ: PFSF
PFSF Trading
47.06% G/L:
$0.05 Last:
100,000 Volume:
$0.05 Open:
